Navigation Links
Promising Data on Cognitive Effects of Safinamide in Early,Parkinson's Disease

for diseases of the Central Nervous System and pain. Newron is undertaking phase III trials with safinamide, a unique molecule with multiple mechanisms of action, for the treatment of PD in conjunction with its partner, Merck Serono S.A., which has the rights to develop the compound in PD, Alzheimer´s disease, other cognitive disorders and Restless Legs Syndrome. Recent results of a six-month phase III trial of safinamide in PD demonstrated its benefit in motor symptoms and activities of daily living, as well as its improvement in cognitive function, and good tolerability. Newron and Merck Serono are planning to expand the development of safinamide to exploit its potential in Alzheimer´s disease. Phase II trials with safinamide in Restless Legs Syndrome have shown promising results. Newron is also conducting phase II trials with ralfinamide for the treatment of neuropathic pain. The drug has potential benefit in inflammatory pain, as well. Newron´s clinical pipeline is supported by a portfolio of early-stage proprietary compounds generated by its ion channel drug discovery platform. Newron is headquartered in Bresso, near Milan, Italy. The company is listed at SWX Swiss Exchange, trading symbol NWRN.
About Merck Serono S.A.
Merck Serono S.A. is a global biotechnology leader, with sales in over 90 countries. The Company is the world leader in reproductive health, with Gonal-f®, Luveris® and Ovidrel®/Ovitrelle®. It has strong market positions in neurology, with Rebif®, as well as in metabolism and growth, with Saizen®, Serostim® and Zorbtive™. The Company has recently entered the psoriasis area with Raptiva®. Merck Serono's research programs are focused on growing these businesses and on establishing new therapeutic areas, including oncology and autoimmune diseases.
Bearer shares of Merck Serono S.A., the holding company, are traded on the virt-x (SEO).


About Merck
Merc
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
5. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
6. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
7. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
8. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
9. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
10. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
11. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
Post Your Comments:
(Date:9/18/2014)... BURLINGTON, Mass. , Sept. 18, 2014  Decision ... launched anti-vascular endothelial growth factor (VEGF) agent for wet ... and Medicare Advantage plans as Genentech,s Lucentis, which is ... although surveyed managed care organization (MCO) directors do not ... Eylea is slightly more likely than Lucentis to be ...
(Date:9/18/2014)... Pa. , Sept. 18, 2014 /PRNewswire/ ... solutions, was recognized as the Disruptive Innovator ... its ePharmaONE cloud-based eClinical platform. This solution ... electronic trial master file (eTMF), a remote ... and ePharmaSolutions, ReferralPlus+ patient screening and matching ...
(Date:9/18/2014)... Sept. 18, 2014  A $3 million grant from ... University of Michigan to establish a national center of ... Center for Aging Research at U-M will focus on ... slow the effects of aging and postpone diseases in ... that can help develop medications that may help people ...
Breaking Medicine Technology:Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3
... bolstering current systems for assessing and monitoring drug safety, researchers ... combines multiple forms of widely available data to predict adverse ... of drug safety issues as they accumulate over time in ... issues years in advance. This study, led by ...
... Food and Drug Administration is warning consumers again not to ... and sold by various companies, due to serious potential health ... Massager is a personal massage device sold in retail ... provide users with a deep tissue massage to the neck, ...
Cached Medicine Technology:Taking a Predictive Approach to Identifying Adverse Drug Reactions 2Taking a Predictive Approach to Identifying Adverse Drug Reactions 3FDA: Do Not Use ShoulderFlex Massagers 2FDA: Do Not Use ShoulderFlex Massagers 3
(Date:9/18/2014)... 2014 (HealthDay News) -- Older people become more physically ... the balance of stress hormones during bereavement changes with ... who are grieving are more likely to have weakened ... "During the difficult weeks and months after loss, we ... most abundant type of white blood cell and as ...
(Date:9/18/2014)... San Luis Obispo, CA (PRWEB) September 18, 2014 ... Bunion Bootie introduced their newest, patent pending bunion splint ... , As one loyalist, Rosa, wrote: "I was absolutely delighted. ... comfortable... I honestly forget I am wearing them. THANK YOU ... the recently introduced design by saying, "The hole used to ...
(Date:9/18/2014)... Mozes HealthDay Reporter , THURSDAY, ... emergency room waiting times, patients seeking care at larger urban ... clock than those seen at smaller or more rural facilities, ... ability to provide timely emergency care varies dramatically across hospitals ... the new research, Dr. Renee Hsia, an associate professor at ...
(Date:9/18/2014)... Chest Physicians (CHEST) together with the Chinese Thoracic ... of CTS that CHEST World Congress 2016 will ... critical care, and sleep medicine from around the ... slated for spring 2016. , CHEST World ... hands-on simulation training, keynote addresses, presentations by leading ...
(Date:9/18/2014)... Seattle, WA (PRWEB) September 18, 2014 ... management organizations, has published a white paper, “Advancing ... Optimization of Health Information Technology.” , Authors Jeff ... PCMH CCE provide guidance to organizations engaged in the ... showing how health IT can bolster PCMH objectives, such ...
Breaking Medicine News(10 mins):Health News:Grief Can Weigh on Immune System in Older Folks, Study Says 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3Health News:ER Waiting Times Vary Significantly, Studies Find 2Health News:ER Waiting Times Vary Significantly, Studies Find 3Health News:CHEST announces China as site of CHEST World Congress 2016 2Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2
... recipient,s tissue, study finds, , SUNDAY, Nov. 22 (HealthDay ... -- a missing gene -- boosts the risk that ... complication called graft-versus-host disease. , The immune system-related ... variation and the donor does not. , When ...
... ... can be both fun and joyous. It can also be stressful and tiring ... foods -- factors that can, over time, increase your risk of cancer. That,s ... 10 Food Tips that can help ensure a happier, more healthful holiday season, ...
... WASHINGTON, Nov. 21 Tonight, in a partisan vote, the ... the government takeover of health care. Among the several objectionable ... and individual mandates, is the government funding for elective abortion, ... bill provides subsidies for private plans that cover elective abortion. ...
... Nov. 21 Milvia Lopez, by her attorney MICHAEL STEWART ... Court, New York County, bearing Index # 112888/2009. The complaint ... ("TEE") at ST. VINCENT,S HOSPITAL , doctors used an ... The complaint alleges that several hours after being discharged from ...
... , LONDON, November 21, 2009 Test Test Test ... Test Test,Test Test Test Test Test Test Test Test Test Test Test Test ... Test , More test More test More test More ... test More test More test More test More,test More test , , ...
... ... available on the iPhone and iPod Touch. , ... Mountain View, CA (PRWEB) November 21, 2009 -- HAPPYneuron,s most popular and ... designed to help banish that ,tip of the tongue, syndrome forever. , , ,The SplitWords ...
Cached Medicine News:Health News:Top 10 Food Tips for the Holidays from the National Foundation for Cancer Research 2Health News:Top 10 Food Tips for the Holidays from the National Foundation for Cancer Research 3Health News:FRC: Senate Votes to Proceed with Abortion Funding Debacle 2Health News:Patient Files Suit Against St. Vincent's Hospital in New York City as a Result of the Alleged Use by the Hospital of an HIV Infected Device During a Routine Procedure 2Health News:HAPPYneuron releases iPhone Brain Game 2Health News:HAPPYneuron releases iPhone Brain Game 3
... 4, 8, or 12 channel pipettors. Angled sides ... of the solution. Corners have pouring lips to ... polystyrene containing no regrinds. Sterile 5/bag packaging for ... mm W x 152 mm L x 35 ...
Volume: 10 ml; Volume Graduation: 1/10 ml...
... Gilsons Pipette Aid, which is for use ... rapidly, and comfortably with precision. It works with ... the volume range from 1 mL to 100 ... valve and replaceable membrane filters, which protect the ...
Inquire...
Medicine Products: